A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
← catalyst calendarSponsored by Sutro Biopharma, Inc. (industry) · STRO — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
58actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Terminated Early
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-22 | actual | When the study began enrolling |
| Primary completion | 2025-06-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-01 | actual | The whole study's end, after follow-up |
| First posted | 2022-01-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Ovarian Carcinoma
- Ovary Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
Interventions
- Drug: STRO-002
- Drug: Bevacizumab — also filed as Avastin
Primary outcomes
what the primary-completion date above is the date OFPart 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapy
measured From baseline through end of study (approximately 24 months)
Part 1 - Determine the recommended phase 2 dose (RP2D) of STRO-002/bevacizumab
measured From baseline through end of study (approximately 24 months)
Publications
- PMID 36459691 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · STRO's whole pipeline · Catalyst calendar · Every registered study · What changed